Abstract
Objective. To assess the antihypertensive efficacy of monotherapy with Nifedipine Retard, Enalapril and Metoprolol in view of polymorphism of genes associated with lipid metabolism, renin-angiotensin system, β-adrenoreceptor and apoptosis cascade in patients with essential hypertension. Design and methods. 150 Tatar hypertensive patients were included, and blood pressure monitoring and gene polymorphism determination were performed. Antihypertensive therapy was prescribed for one month. Results. There are associations between antihypertensive efficacy and the number of genetic markers in hypertensive patients. We suppose that protein products encoded by GluR2, HIF-1А, CASP9, Ephrin-B3 genes play a role either in blood pressure regulation or in the mechanism of blood pressure decrease under therapy with Nifedipine Retard, Enalapril or Metoprolol. Conclusion. GluR2, HIF-1А, CASP9, Ephrin-B3 genes polymorphisms can be used to predict the efficacy of treatment with Nifedipine Retard, Enalapril and Metoprolol in hypertensive patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
